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Abstract: The aryl hydrocarbon receptor (AHR) is a cytosolic receptor which is involved in diverse
cellular events in humans. The most well-characterized function of AHR is its ability to upregulate
gene transcription after exposure to its ligands, such as environmental toxicants, dietary antioxidants,
drugs, and endogenous ligands. The cellular content of AHR is partly controlled by its degradation
via the ubiquitin–proteasome system and the lysosome-dependent autophagy. We used human
cervical cancer (HeLa) cells to investigate how AHR undergoes protein degradation and how its
activity is modulated. Since the glycogen synthase kinase 3 beta (GSK3β)-mediated phosphorylation
can trigger protein degradation and substrates of GSK3β contain stretches of serine/threonine
residues which can be found in AHR, we examined whether degradation and activity of AHR can
be controlled by GSK3β. We observed that AHR undergoes the GSK3β-dependent, LC3-mediated
lysosomal degradation without ligand treatment. The AHR can be phosphorylated in a GSK3βdependent manner at three putative sites (S436/S440/S444, S689/S693/T697, and S723/S727/T731),
which leads to lysosomal degradation of the AHR protein. Inhibition of the GSK3β activity suppresses
the ligand-activated transcription of an AHR target gene in HeLa, human liver cancer (Hep3B),
and human breast cancer (MCF-7) cells. Collectively, our findings support that phosphorylation
of AHR by GSK3β is essential for the optimal activation of its target gene transcription and this
phosphorylation may partake as an “off” switch by subjecting the receptor to lysosomal degradation.
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1. Introduction
The aryl hydrocarbon receptor (AHR) is a cellular sensor of environmental pollutants/carcinogens, endogenous ligands, and numerous dietary flavonoids and their derivatives [1]. Upon ligand binding, the AHR cytosolic complex changes conformation to reveal
its nuclear localization motif, resulting in nuclear entry. The nuclear AHR dimerizes with
aryl hydrocarbon receptor nuclear translocator (ARNT) to form an active transcription factor: it binds to the dioxin response element, recruits co-activators locally to alter chromatin
structure, and eventually allows optimal assembly of the preinitiation complex for gene
transcription. Although AHR is best known for its action as a ligand-activated transcription
factor which regulates transcription of xenobiotic metabolizing enzyme genes, the biological role of this receptor is rather complex, and yet very interesting. For example, recent
reports show that AHR plays an intricate role in seemingly diverse biological processes and
diseases, namely autoimmune diseases [2–4], cancers and cell proliferation [5–9], cancer
stem cell differentiation [10], respiratory disorders [11,12], atopic dermatitis [13–15], bone
disorders [16], antiviral response [17], and adipocyte differentiation [18]. This receptor is
even implicated in the SARS-CoV-2 pathophysiology [19]. Obviously AHR has become
an attractive target for drug development; thus, any means to modulate its function in
selective tissues is highly desirable. AHR normally translocates into the nucleus after
ligand binding, followed by degradation via the ubiquitin-proteasome system [20–22]. Interestingly, even without addition of an exogenous ligand, we showed that AHR undergoes
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Figure 1. GSK3β phosphorylation sites. (A) GSK3β phosphorylation consensus sequence. (B) GSK3β
phosphorylation sites of β-catenin. (C) Three putative GSK3β phosphorylation sites of the human
AHR (amino acid 1-848) which show best match to the consensus sequence. The numbers indicate
the amino acid locations of the primary sequence. Orange font represents the serine and threonine
sites for GSK3β phosphorylation. S45 (bold) of β-catenin represents the priming site of casein kinase
1. Phosphorylation of the priming site is necessary for GSK phosphorylation.
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Figure 1. GSK3β phosphorylation sites. (A) GSK3β phosphorylation consensus sequence. (B) GSK3β
phosphorylation sites of β-catenin. (C) Three putative GSK3β phosphorylation sites of the human
AHR (amino acid 1-848) which show best match to the consensus sequence. The numbers indicate
the amino acid locations of the primary sequence. Orange font represents the serine and threonine
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sites for GSK3β phosphorylation. S45 (bold) of β-catenin represents the priming site of casein kinase
1. Phosphorylation of the priming site is necessary for GSK phosphorylation.
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AHR degradation. We performed experiments using a proteasome inhibitor MG132 and
an autophagy inhibitor chloroquine (CQ). We observed that MG132 surprisingly decreased the amount of AHR protein in HeLa cells that were transiently transfected with
either a plasmid carrying the HA fusion of GSK3β cDNA or with no plasmid (Figure 3A).
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Figure 3. AHR undergoes the LC-3-mediated autophagy after GSK3β phosphorylation. (A) AHR protein levels ± HA-
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2.3. GSK3β Phosphorylates AHR in HeLa Cells
Next, we examined whether AHR could be phosphorylated by GSK3β. Phos-tag reagent, which has been successfully used by other researchers to detect phosphorylated
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region showed a time- and dose-dependent decrease after phosphatase (λ-PP) treatment,
supporting that these bands represent the phosphorylated AHR (Figure 4B). After λ-PP
treatment, the top region intensities were weaker while the unphosphorylated AHR band
intensity increased. Thus, we quantified our data by the ratio of the intensity of the
phosphorylated region to the intensity of the total AHR, which was the combined intensity
of phosphorylated and unphosphorylated AHR. Inhibition of GSK3β by TDG yielded
more unphosphorylated AHR and showed that the phosphorylated AHR/total AHR value
decreased to about 50% (Figure 4C). Transient expression of the HA fusion of GSK3β
increased the phosphorylated AHR region intensity and decreased the unphosphorylated
AHR intensity. The phosphorylated AHR/total AHR value increased to 2-fold when HAGSK3β was transiently expressed (Figure 4D). Taken together, AHR can be phosphorylated
in a GSK3β-dependent manner.
2.4. Mutational Analysis Reveals Three Putative GSK3β Phosphorylation Regions of AHR
To further investigate whether AHR would be a substrate of GSK3β, we used two
truncated human AHR, namely C∆553 (amino acid 1–295) and N∆515 (amino acid 516-848),
that were fused to GFP to approximate the phosphorylation location(s) (Figure 5A). Neither
of these two GFP fusions responded to TDG inhibition (Figure 5B,C) whereas both the
endogenous AHR and GFP-AHR controls did (Figure 5B–D). There are three stretches of
serine and threonine residues of AHR that fulfill the requirement of an GSK3β substrate:
they are S436/S440/S444, S689/S693/T697, and S723/S727/T731 (Figure 1). These locations match the consensus GSK3β recognition motif and the GSK3β phosphorylation sites
of β-catenin. We mutated these serine and threonine residues to alanine and generated
three GFP fusion mutants, namely M1 (S436A/S440A/S444A), M2 (S689A/S693A/T697A),
and M3 (S723A/S727A/T731A) (Figure 5A). After treatment of 40 µM TDG, only HeLa cells
transfected with the M2-GFP fusion showed no statistically significant increase whereas
M1- and M3-GFP fusions showed modest increase after GSK3β inhibition by TDG (1.26- to
1.34-fold), when compared to the endogenous AHR and AHR-GFP fusion with a somewhat
higher increase upon TDG treatment (1.39- to 1.54-fold) (Figure 5E–G).
Next, we examined whether resistance to GSK3β control would translate into resistance to lysosomal degradation. Our results showed that levels of GFP fusions of C∆553
and N∆515 after transient transfection into HeLa cells were not altered after CQ, which is
an autophagy inhibitor, treatment whereas the endogenous AHR and AHR-GFP fusion
showed higher levels after CQ treatment (Figure 6A–C). In addition, unlike the endogenous
AHR in HeLa cells which showed about 2–2.5-fold increase upon CQ treatment, levels
of the GFP fusions of all three mutants (M1-M3) after transient transfection were only
modestly increased (1.23- to 1.27-fold) (Figure 6D–F) while the AHR-GFP levels were increased by 1.8-fold in the presence of CQ. Collectively, these results revealed three putative
GSK3β phosphorylation regions of AHR which are essential for the lysosomal degradation
of AHR.
2.5. p23 Is Essential for the GSK3β-Mediated Degradation of AHR in HeLa Cells
We previously reported that the basal AHR protein levels are regulated by selective
autophagy and this degradation is more pronounced in the stable p23 knockdown (p23KD)
HeLa cells, resulting in about 50% of the AHR content when compared to the wild type
content [23]. When we treated the p23KD HeLa cells with TDG (10–40 µM), only 40 µM
TDG increased AHR protein level significantly to 1.3-fold (Figure 7A), which was lower
than what we observed in HeLa cells (1.7-fold, Figure 2A). LiCl (5 mM), on the other
hand, could not alter the AHR protein levels in p23KD HeLa cells (Figure 7B). Transient
expression of the HA fusion of GSK3β in p23KD HeLa cells decreased the β-catenin
protein levels as expected. However, the AHR protein levels were not altered (Figure 7C).
Consistently, LiCl caused an increase of the β-catenin protein levels in p23 KD HeLa cells
(Figure 7D) but elicited no effect on the AHR protein levels. To further confirm that p23 is
essential for the GSK3β effect on AHR, we examined whether this GSK3β effect could be
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strate: they are S436/S440/S444, S689/S693/T697, and S723/S727/T731 (Figure 1). These locations match the consensus GSK3β recognition motif and the GSK3β phosphorylation
sites of β-catenin. We mutated these serine and threonine residues to alanine and generated three GFP fusion mutants, namely M1 (S436A/S440A/S444A), M2 (S689A/S693A/T697A),
and M3 (S723A/S727A/T731A) (Figure 5A). After treatment of 10 μM TDG, only HeLa cells
transfected with the M2-GFP fusion showed no statistically significant increase whereas M1and M3-GFP fusions showed modest increase after GSK3β inhibition by TDG (1.26- to 1.34fold), when compared to the endogenous AHR and AHR-GFP fusion with a somewhat higher
increase upon TDG treatment (1.39- to 1.54-fold) (Figure 5E-G).
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an autophagy inhibitor, treatment whereas the endogenous AHR and AHR-GFP fusion
showed higher levels after CQ treatment (Figure 6A-C). In addition, unlike the endogenous AHR in HeLa cells which showed about 2–2.5-fold increase upon CQ treatment, levels of the GFP fusions of all three mutants (M1-M3) after transient transfection were only
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modestly increased (1.23- to 1.27-fold) (Figure 6D-F) while the AHR-GFP levels were
creased by 1.8-fold in the presence of CQ. Collectively, these results revealed three putative GSK3β phosphorylation regions of AHR which are essential for the lysosomal degradation of AHR.
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with Sidak multiple comparisons test was performed to determine statistical significance. For A to F, each Western lane
contained 30 µg of whole-cell lysate. Data were normalized by total protein stain. N∆515-GFP (6B) was detected by the
GFP antibody since this construct could not be detected by SA210 AHR antibody while all other GFP fusions of AHR and
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Figure 7. Down-regulation of p23 in HeLa cells causes AHR not responsive to GSK3β regulation. (A) AHR protein levels
were not altered by 8-h treatment of 10 µM or 20µM TDG in p23 stable knockdown (p23KD) HeLa cells. Treatment of
40 µM TDG increased AHR protein levels to 1.3-fold. The images are representative of the replicate data (means ± SD,
n = 3, ** p < 0.01, ns represents not significant). DMSO group (treated for 8 h) was arbitrarily set as one (with no error
bar) for data normalization. One-way ANOVA with Dunnett multiple comparisons test was performed to determine
statistical significance. (B) Treatment of 5 mM LiCl for 6 h did not alter AHR protein levels in p23KD HeLa cells. The images
are representative of the replicate data (means ± SD, n = 3, ns represents not significant). No LiCl (no treatment) group
was arbitrarily set as one (with no error bar) for data normalization. Unpaired t-test with Welch’s correction was used to
determine the statistical significance. (C) β-catenin protein levels decreased while AHR protein levels showed no significant
difference after transient expression of HA-GSK3β (72 h after transient transfection) in p23KD HeLa cells. The images
are representative of the replicate data (means ± SD, n = 3, * p < 0.05, ns represents not significant). No plasmid group
(NP) represents cells undergoing the same transient transfection protocol without the HA-GSK3β expressing plasmid and
was arbitrarily set as one (with no error bar) for data normalization. Unpaired t-test with Welch’s correction was used to
determine the statistical significance. (D) β-catenin protein levels increased in p23KD HeLa cells after treatment of 5 mM
LiCl for 6 h. The images are representative of the replicate data (means ± SD, n = 3 in one experiment, which was repeated
once with similar results, *** p < 0.001). No LiCl (no treatment) group was arbitrarily set as one for data normalization.
Unpaired t-test was used to determine the statistical significance. (E) p23KD HeLa cells were transiently transfected with
the plasmid expressing GFP or GFP-p23. Transient expression of GFP-p23 caused AHR protein levels to increase when cells
were treated 20 µM TDG for 8 h. The images are representative of the replicate data (means ± SD, n = 3 in one experiment,
which was repeated once with similar results, * p < 0.05, *** p < 0.001, ns represents not significant). DMSO treatment
group of GFP-transfected cells was arbitrarily set as one for data normalization. Two-way ANOVA with Sidak multiple
comparisons test was performed to determine statistical significance. For A to E, each Western lane contained 30 µg of
whole-cell lysate. Data in A were normalized by β-actin (as shown) whereas the rest of the data were normalized by total
protein stain.

2.6. GSK3β-Mediated AHR Phosphorylation Is Necessary for Optimal Activation of the AHR
Target Gene Transcription in Human Cervical, Liver, and Breast Cancer Cells
Next, we examined whether the AHR function could be regulated by GSK3β. To do
this, we measured the prototypical induction of the cytochrome P450 1A1 gene transcription
by an AHR ligand in HeLa cells in the presence or absence of TDG. We observed that the
cytochrome P450 1A1 (cyp1a1) transcript was induced in HeLa cells, as expected, by two
well-known AHR ligands beta-naphthoflavone (βNF) and 3-methylcholanthrene (3MC) to
5- and 19-fold, respectively, and this induction was suppressed effectively by a classical
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AHR antagonist CH223191 (Figure 8A,B). However, TDG alone did not alter the cyp1a1
transcript levels but significantly suppressed the βNF (5-fold to 3-fold) and 3MC (19-fold
to 7-fold) dependent cyp1a1 gene transcription. The effect of TDG and CH223191 was
synergistic, which was particularly apparent in the case of the 3MC-induced cyp1a1 gene
transcription. This observation suggested that TDG and CH223191 likely inhibit the AHR
function via different mechanisms. Downregulation of GSK3β expression via a GSK3β
specific shRNA in HeLa cells significantly suppressed the ability of an AHR ligand (βNF,
benzo[a]pyrene (BaP) or 3MC) to induce the cyp1a1 gene transcription (Figure 8C–E).
Furthermore, knockdown of GSK3β abolished the TDG suppression of the 3MC-mediated
AHR
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEWactivity (Figure 8F). In addition to what we observed in HeLa cells, this suppression
13 of 23
of the 3MC activation of cyp1a1 gene transcription by TDG was also observed in Hep3B
(180-fold to 92-fold) and MCF-7 (1864-fold to 961-fold) cells (Figure 8G,H). Collectively,
our results showed that phosphorylation of AHR by GSK3β is essential for optimal AHR
activity in terms of the ligand-activated gene transcription.
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Figure 8. Reduction of GSK3β activity suppresses the ligand-dependent activation of AHR target gene transcription. For A
and B, HeLa cells were treated with 40 µM TDG for 9 h. At 5-h post-TDG treatment, cells were treated with either (A) 10 µM
βNF, 10 µM CH223191 or both or (B) 1 µM 3MC, 10 µM CH223191 or both. TDG were able to partially block the increase of
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3. Discussion
GSK3β generally regulates its substrate stability (via phosphorylation) by promoting the binding of E3 ligases, such as β-transducin repeat containing proteins (β-TrCP),
and eventually targeting its substrates for proteasomal degradation [28]. We previously
discovered that without ligand treatment, AHR protein levels are regulated by selective
autophagy while inhibition of proteasomal degradation by MG132 further decreases the
AHR protein content [23]. This MG132 effect on AHR has also been observed with the
GSK3β-mediated AHR degradation which involves the formation of the K63-linked ubiquitination of AHR, revealing the flexibility of degradation mechanisms that can be triggered
by GSK3β phosphorylation.
GSK3β is involved in the regulation of mammalian circadian rhythm [32]. In particular, there are at least two PAS proteins, namely period circadian regulator 2 (PER2)
and circadian locomotor output cycles kaput (CLOCK), that are GSK3β substrates [32,33].
These proteins are in the same family of AHR, making it intriguing that AHR is also
regulated by GSK3β. Another notable GSK3β substrate is β-catenin. There are many
aspects of functional dependence between AHR and β-catenin. AHR has been shown as a
β-catenin target gene in prostate cancer cells so that increased β-catenin activity leads to
increased AHR expression [34]. However, increased AHR function promotes proteasomal
degradation of β-catenin since AHR is a E3 ligase which recognizes β-catenin as one of
its substrate proteins for degradation [35]. Functionally speaking, AHR and β-catenin
operate synergistically to activate the cyp1a1 gene transcription [36,37]. Interestingly, both
AHR and β-catenin activities are controlled by protein degradation mechanisms: AHR
undergoes proteasomal degradation after ligand activation whereas β-catenin undergoes
proteasomal degradation, limiting its transactivation of the Wnt target genes. Since AHR
contains several stretches of serine and threonine residues in its transactivation region
which are similar to the GSK3β phosphorylation sites of β-catenin, we explored whether
GSK3β would play any role in AHR degradation. Surprisingly, but interestingly, GSK3β
causes AHR degradation via autophagy rather than the ubiquitin-proteasome system. In
an effort to validate the degradation mechanism, we captured proteasomal degradation
using MG132 by proving that the levels of β-catenin were restored upon MG132 treatment.
In contrast, MG132 caused reduction of the AHR levels when GSK3β was inhibited by
TDG, clearly supporting a mechanism that is different from β-catenin degradation. This
reduction is explained by the fact that MG132 can trigger autophagy [38], resulting in
further degradation of AHR. One may argue that accumulation of AHR could still be
proteasome-mediated since increased p62 levels, which is caused by an autophagy inhibitor such as CQ, has been shown to increase the half-life of proteasome substrates [39].
However, while such substrates accumulate after MG132 treatment [39], AHR did not,
supporting that AHR undergoes lysosomal degradation via autophagy. We observed
a higher autophagic flux in HA-GSK3β expressing HeLa cells. GSK3β phosphorylates
HIV Tat-interactive protein 60 kDa (TIP60), which in turn activates Unc-51 like kinase-1
(ULK1), a key autophagy-related protein that plays an important role in autophagy initiation. Through this GSK3β-TIP60-ULK1 pathway, autophagy is induced under ER-stress
or growth factor deprivation [40,41]. However, if the GSK3β-mediated degradation of
AHR were merely caused by induction of autophagy, p23 knockdown HeLa cells would
have been more pronounced in the suppression of the AHR levels since AHR is more
prone to degradation via autophagy when p23 is down-regulated [23]. On the contrary, the
GSK3β-mediated AHR degradation is less apparent when the p23 levels are downregulated.
The relationship between GSK3β and p23 in affecting AHR degradation is reminiscent
of the role of Axin, which is part of the β-catenin destruction complex, in facilitating the
GSK3β-mediated degradation of β-catenin [42]. Perhaps p23 plays a role in conforming
the structure of AHR to be recognizable by GSK3β. Collectively, our results are consistent
with the conclusion that GSK3β phosphorylates AHR in a p23-dependent manner and in
turn causes its lysosomal degradation, which is heightened by active GSK3β.
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The primary sequence of AHR has multiple locations containing two or more serine
and threonine residues that are 3-4 amino acids apart—the minimal requirement for GSK3β
recognition. Among them, there are three AHR regions that match the consensus GSK3β
targeting sequence the best. We performed mutational analysis to convert every serine
or threonine residue into alanine in all three (M1-M3) regions. Results from our deletion
studies using C∆553 (amino acid 1-295) and N∆515 (amino acid 516-848) revealed that
amino acids between 296 and 515 are likely essential for the GSK3β-mediated degradation
of AHR since both AHR deletion construct levels were unaltered upon TDG treatment.
We, however, cannot rule out the possibility that protein folding could be distorted in
these deletion constructs, preventing them to be recognized for lysosomal degradation.
Nevertheless, since M1 is located within this 296-515 region, we initially predicted that
M1, but not M2 and M3, would contain the GSK3β phosphorylation sites. We also realized
that more than one region could be phosphorylated by GSK3β since Shaggy, a drosophila
orthologue of GSK3β, phosphorylates Cubitus interruptus (Ci) at two distinct regions that
are more than 30 amino acids apart [43]. Interestingly, all three mutants (M1-M3) showed
some resistance to GSK3β inhibition by TDG with the order of M2 > M3 ~ M1, suggesting
that M2 (rather than M1) likely contains the GSK3β phosphorylation sites. Moreover, all
three mutants showed significant, but not complete, resistance to lysosomal degradation by
CQ, suggesting that all three regions could mediate AHR lysosomal degradation. GSK3β
phosphorylation often works in conjunction with another kinase, since GSK3β substrates
are usually “primed” by a kinase, followed by GSK3β phosphorylation [28]. However, the
interplay among kinases targeting M1-M3 is much more complicated since the reported
“primed” kinase site is only few amino acids away from the GSK3β site, which cannot
explain how M1–3 sites could mutually affect one another. We cannot rule out the possibility
that M1 and M3 regions could be targeted by a kinase which might somehow direct AHR
toward lysosomal degradation, or abrogation of phosphorylation at the M1/M3 mutated
regions by a kinase might cause a conformational change that would interfere with the
GSK3β phosphorylation at the M2 region. On the contrary, phosphorylation of AHR by
GSK3β could cause a conformational change that would allow another kinase to further
phosphorylate AHR.
Inhibition of extracellular signal-regulated (Erk) kinase by inhibitors, such as U0126
and PD98059, increases the AHR protein levels in mouse hepatoma Hepa1c1c7 cells [44].
Expression of a constitutively active form of MEK1 in Hepa1c1c7 cells reduces the AHR
protein levels by promoting the Erk kinase-dependent phosphorylation of AHR. Interestingly, these researchers showed that the ligand-dependent function of AHR is suppressed
by these Erk kinase inhibitors, similar to what we observed when GSK3β is inhibited or
downregulated. However, it is apparent that these Erk inhibitors can physically interfere
with the action of a more potent AHR ligand since U0126 is an AHR activator whereas
PD98059 is an AHR antagonist [44]. In our case, suppression of the AHR transcriptional
activation is likely mediated directly through the action of GSK3β in phosphorylating AHR,
since inhibition of GSK3β (by TDG) and downregulation of GSK3β showed similar degrees
of suppression. The treatment of TDG in the GSK3β knockdown HeLa cells did not further
suppress the AHR transactivation function. Moreover, the putative phosphorylation sites
(M1-M3) of AHR overlap with its region required for physical recruitment of coactivators,
making it plausible that phosphorylation positively affects the transcriptional activation
of AHR [44]. Our results reveal interesting insights on how AHR signals: AHR is more
active when it is phosphorylated; in other words, phosphorylation is a means to modulate
AHR function. In addition, phosphorylation of AHR is also a trigger for its own lysosomal
degradation, i.e., it acts as an “off” switch since the half-life of the phosphorylated AHR
is governed by lysosomal degradation (Figure 9). AHR phosphorylation may work in
conjunction with the proposed “off” switches of AHR—proteasomal degradation of AHR
after ligand activation [21] and upregulation of the AHR repressor (ahrr) gene transcription
by AHR [45].
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IRDye 680 anti-rabbit, anti-mouse secondary antibody, and IRDye 800CW streptavidin
were purchased from LI-COR Bioscience (Lincoln, NE, USA). GlutaMAX-I, penicillin, and
streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). HyClone FBS and
HyClone DMEM were purchased from Fisher scientific (Rockford, IL, USA).
4.2. Cell Culture
HeLa and Hep3B cell lines were authenticated by ATCC. MCF-7 cell line was obtained
from ATCC. AD-293 cells were obtained from Agilent Technologies (Santa Clara, CA, USA).
All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mM
GlutaMAX-I, 10 U/mL of penicillin, and 10 mg/mL of streptomycin at 37 ◦ C and 5% CO2 .
4.3. Generation of p23 Stable Knockdown Cells
We used our previously published protocol [23] to generate new p23 stable knockdown
HeLa cells for this study. In brief, on day 1, AD-293 cells (about 7 × 105 cells) were seeded
in 5 mL of DMEM (10% FBS) without antibiotics in a 25 cm2 flask and incubated at
37 ◦ C and 5% CO2 overnight. On day 2, cells should reach 50–80% confluence and in
fresh medium without antibiotics. Transfection was performed in the late afternoon using
EndoFectin transfection reagent (2:1 DNA ratio) with the plasmid cocktail as follows: 2.5 µg
of p23 shRNA plasmid (#1475), 1.875 µg of the pCMV-dR8.2 dvpr packaging plasmid, and
0.625 µg of the VSV-G envelope plasmid. Fresh complete medium was exchanged 15 h
after transfection (day 3). After 24 h, medium which contained the virus was collected
(day 4) and stored at 4 ◦ C. Another 5 mL of fresh complete medium was added to cells and
was collected 24 h afterwards (day 5). The combined medium was centrifuged at 400× g
for 5 min to remove any AD-293 cells that were inadvertently collected. The resulting
supernatant was used for infection. Lentiviral infection of HeLa cells was performed by first
seeding cells in a 75 cm2 flask to 50–70% confluence. Fresh complete medium containing
8 µg/mL of polybrene was exchanged. Supernatant containing lentiviral particles (0.5 mL)
was then added. The fresh complete medium was exchanged 24 h after infection. The
selection was started by adding 1.5 µg/mL of puromycin 48–54 h after infection. Western
analysis was performed to determine the p23 protein levels after 2–3 passages.
4.4. Transient Transfection
Cells were grown in 6-well plates overnight (16-18 h) and transfection was initiated
when cells were about 90-95% confluence. Cells were transfected with 3 µg of plasmid (4 µg
for HA-GSK3β) and 6 µL of EndoFectin reagent (8 µL for HA-GSK3β). Fresh complete
medium was exchanged 24 h after transfection. HA-GSK3β and GSK3β shRNA plasmids
were transfected for 72 h. Usually, we initiated cell treatment at 70 h post transfection. pGFP
plasmids were transfected for 48 h with cell treatment initiated at 48 h post transfection.
4.5. Whole-Cell Lysate Preparation
Cells were harvested using cold 1xPBS by mechanical scrapping. Cell pellets were
resuspended using cold lysis buffer (25 mM HEPES, pH 7.4, 0.4 M KCl, 1 mM EDTA,
1 mM DTT, 10% glycerol, 1% NP-40, 1 mM PMSF, and 2 µg/mL of leupeptin) of 3 times
the volume of cell pellets. After three cycles of freeze/thaw, lysates were kept on ice for
30 min and were then centrifuged at 16,000× g for 10 to 20 min at 4 ◦ C. The supernatants
were defined as whole-cell lysates and were subjected to BCA assay to determine the
protein concentration.
4.6. Western Blot Analysis
The protocol for Western blot analysis was described previously [23] with minor modification. In brief, if 15% instead of 10% acrylamide gels were used, they were transferred
via full submersion for an additional one h (3 h total) at 4 ◦ C. After the wet transfer, total
protein staining was performed using LI-COR REVERT Total Protein Stain. Membranes
for the examination of LC3B levels were dried for at least 40 min and wet with PBS before
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blocking. The transferred nitrocellulose membranes were blocked in PBS with 5% BSA
for 1 h. Dilutions for antibodies were as follows: 1:1000 for anti-p23 JJ3 and anti-LC3B
L7543; 1:2000 for anti-AHR SA210; 1:5000 for anti-β-actin AM4302; 1:200 for anti-GSK3β
0011-A and anti-β-catenin 15B8. If not specified, Western bands were normalized using
total protein stain. Results were obtained and analyzed using a LI-COR Odyssey CLx
imaging system.
4.7. RT-qPCR
RT-qPCR was performed as described previously [47]. In brief, when HeLa cells in a
75 cm2 flask reached 90–100% confluence, 5% of cells (0.3 mL of 6 mL total cell suspension)
were seeded onto each well of a 6-well plate. After incubation for 16–18 h, cells were
treated with different reagents or transfected with the GSK3β shRNA at 90–95% confluence.
For Hep3B and MCF-7 cells, when cells in 75 cm2 flask reached 95% confluence, 8.3% of
cells (0.5 mL of 6 mL total cell suspension) were seeded onto each well of a 6-well plate.
After incubation for about 24 h, cells reached 80–90% confluence and were treated with
different reagents. After treatment, media were aspirated, and RNA was extracted using
the Direct-zol kit with TRI reagent. Reverse transcription was performed for 1 µg of RNA
using Epicentre MMLV reverse transcriptase. Quantitative PCR was performed with: 1 µL
of cDNA from reverse transcription solution, 10 µL of Bio-Rad iTaq SYBR green supermix,
and 0.8 pmol sequence-specific primers (cyp1a1 primers are OL109, 50 -GGC CAC ATC
CGG GAC ATC ACA GA-30 and OL110, 50 -TGG GGA TGG TGA AGG GGA CGA A-30 ;
β-actin primers are OL101, 50 -CCA CAC TGT GCC CAT CTA GG-30 and OL102, 50 -AGG
ATC TTC ATG AGG TAG TCA GTC AG-30 ) using a Bio-Rad CFX Connect real-time PCR
machine with the following protocol: 40 cycles of 90 ◦ C for 10 s/60 ◦ C for 1 min with
fluorescence readings taken at 60 ◦ C. The 2 −∆∆Cq method [48] was used to present the
normalized values.
4.8. Immunoprecipitation and K63-TUBE Far-Western Analysis
HeLa cells were seeded and cultured overnight in 6-well plates. Transfection of the
GSK3β shRNA was initiated when cells reached about 90% confluence and was continued
for 72 h. Immunoprecipitation was performed as described previously [23]. In brief,
cells were lysed as described under 4.5 with 4 times the volume of pellet size. Three
deubiquitylase inhibitors, namely 1,10-phenanthroline (5 mM), NEM (10 mM), and PR-619
(50 µM) were added in the lysis buffer for immunoprecipitation experiment with K63TUBE Far-western analysis. About 1.5-2.0 milligrams of whole-cell lysates were used for
immunoprecipitation of AHR using the anti-AHR SA210 antibody (1:200 by volume) for
30 min at room temperature. The pre-equilibrated Protein G Dynabeads (1:200 by volume)
were then added to each sample with the assay buffer: 25 mM HEPES, pH 7.4, 0.15 M NaCl,
1 mM EDTA, 1 mM DTT, 10% glycerol, 0.1% Tween-20, and 1 mg/mL of BSA. The samples
were incubated with a rotation of 60 rpm overnight at 4 ◦ C. The beads were then washed
three times for 5 min each with the assay buffer and then eluted with electrophoresis
sample buffer for SDS-PAGE, followed by Far-western analysis. K63-TUBE biotin (1:1000)
were incubated with the nitrocellulose membrane for 1 h at room temperature and then
with IRDye-800 conjugated streptavidin (1:10,000) for 2 h at room temperature. The wash
step between incubation was the same as in Western analysis. Results were obtained and
analyzed using a LI-COR Odyssey CLx imaging system.
4.9. Phos-Tag Gel SDS-PAGE
Whole-cell lysates were treated with 0, 80 units (1 µL), or 400 units (5 µL) of λ-PP
for 2, 30, or 60 min at 30 ◦ C. To detect the phosphorylated AHR and β-catenin, a gel mix
containing 7.5% acrylamide, 20 µM phos-tag reagent, and 80 µM ZnCl2 was prepared
to make the phos-tag acrylamide gel, according to the manufacturer’s protocol. Bis-Tris
SDS-PAGE system was used with MOPS as the running buffer. SDS-PAGE were performed
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at 4 ◦ C; 55 volts for the stacking gel and 110 volts for the resolving gel. Wet transfer was
performed at 4 ◦ C for 4 h. Western blot analysis was performed as described under 4.6.
4.10. Site-Directed Mutagenesis
QuikChange II lightning kit was used to perform site-directed mutagenesis. All the
procedures were performed strictly according to the manufacturer’s protocol. For the
mutant strand synthesis reaction, 10 ng of the pGFP2-N2-AHR plasmid [24] were used as
the template. Primers are listed in Table 1. The full-length cDNA sequences of all mutant
plasmids were confirmed by sequencing (Functional Biosciences, Madison, WI, USA).
Table 1. M1, M2, and M3 using the pGFP2-N2-AHR plasmid as the template for QuikChange mutagenesis.
Target Sequence

Primer Sequence

S436A-S440A-S444A

Forward(OL904): 50 -a aat ggc act gct gga aaa gac gct
gct acc aca gcc act cta agc aag g -30
Reverse(OL905): 50 -c ctt gct tag agt ggc tgt ggt agc
gtc ttt tcc agc agt gcc att t-30
Forward(OL906): 50 -gag ttc ccc tac aaa gct gaa atg
gat gct atg cct tat gca cag aac ttt att tcc-30
Reverse(OL907): 50 -gga aat aaa gtt ctg tgc ata agg cat
agc atc cat ttc agc ttt gta ggg gaa ctc-30
Forward(OL908): 50 -c tac cct atg ggg gct ttt gaa cca
gcc cca tac ccc gct act tct agt t-30
Reverse(OL909): 50 -a act aga agt agc ggg gta tgg ggc
tgg ttc aaa agc ccc cat agg gta g-30

S689A-S693A-T697A

S723A-S727A-T731A

4.11. Statistical Analysis
GraphPad Prism 9 software (La Jolla, CA, USA) was utilized for statistical analysis.
Two-tailed unpaired t-test and one-wa ay and two-way (or mixed-model) ANOVA with
Sidak, Tukey or Dunnett tests for multiple comparisons were used to determine statistical
significance with * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns, not significant
(p > 0.05). Some specific detail is also mentioned in the figure legends.
5. Conclusions
Phosphorylation of AHR by GSK3β occurs in HeLa cells even without exogenous
ligand treatment. After the GSK3β-mediated phosphorylation, AHR undergoes lysosomal
degradation and is more active in the ligand-activated gene transcription. Inhibition of
GSK3β activity by TDG suppresses the transcriptional activation function of AHR in at
least HeLa, Hep3B, and MCF-7 cells, suggesting that the role of GSK3β in AHR modulation
is likely a general mechanism across many human cell types.
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N-ethylmaleimide
HA fusion of GSK3β
specific tandem ubiquitin binding entity
lysine 63
λ-phosphatase
p23 knockdown
3-methylcholanthrene
beta-naphthoflavone
benzo[a]pyrene
no plasmid
cytochrome P450 1A1
HIV Tat-interactive protein 60 kDa
Unc-51 like kinase-1
AHR repressor

References
1.
2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

Murray, I.A.; Perdew, G.H. How Ah Receptor Ligand Specificity Became Important in Understanding Its Physiological Function.
Int. J. Mol. Sci. 2020, 21, 9614. [CrossRef]
Iyer, S.S.; Gensollen, T.; Gandhi, A.; Oh, S.F.; Neves, J.F.; Collin, F.; Lavin, R.; Serra, C.; Glickman, J.; de Silva, P.S.A.; et al.
Dietary and Microbial Oxazoles Induce Intestinal Inflammation by Modulating Aryl Hydrocarbon Receptor Responses. Cell
2018, 173, 1123–1134.e11. [CrossRef]
Rosser, E.C.; Piper, C.J.M.; Matei, D.E.; Blair, P.A.; Rendeiro, A.F.; Orford, M.; Alber, D.G.; Krausgruber, T.; Catalan, D.;
Klein, N.; et al. Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in
Regulatory B Cells. Cell Metab. 2020, 31, 837–851.e10. [CrossRef]
Kahalehili, H.M.; Newman, N.K.; Pennington, J.M.; Kolluri, S.K.; Kerkvliet, N.I.; Shulzhenko, N.; Morgun, A.; Ehrlich, A.K.
Dietary Indole-3-Carbinol Activates AhR in the Gut, Alters Th17-Microbe Interactions, and Exacerbates Insulitis in NOD Mice.
Front. Immunol. 2020, 11, 606441. [CrossRef] [PubMed]
Garcia-Villatoro, E.L.; DeLuca, J.A.A.; Callaway, E.S.; Allred, K.F.; Davidson, L.A.; Hensel, M.E.; Menon, R.; Ivanov, I.; Safe, S.H.;
Jayaraman, A.; et al. Effects of high-fat diet and intestinal aryl hydrocarbon receptor deletion on colon carcinogenesis. Am. J.
Physiol. Liver Physiol. 2020, 318, G451–G463. [CrossRef]
Zhang, X.; He, B.; Chen, E.; Lu, J.; Wang, J.; Cao, H.; Li, L. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and
migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma. J. Cell. Physiol. 2021, 236, 178–192. [CrossRef]
[PubMed]
Huerta-Yepez, S.; Tirado-Rodriguez, A.; Montecillo-Aguado, M.R.; Yang, J.; Hammock, B.D.; Hankinson, O. Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor
progression. Sci. Rep. 2020, 10, 7843. [CrossRef]
Nothdurft, S.; Thumser-Henner, C.; Breitenbucher, F.; Okimoto, R.A.; Dorsch, M.; Opitz, C.A.; Sadik, A.; Esser, C.; Holzel, M.;
Asthana, S.; et al. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis
2020, 9, 102. [CrossRef]
Sari, Z.; Miko, E.; Kovacs, T.; Janko, L.; Csonka, T.; Lente, G.; Sebo, E.; Toth, J.; Toth, D.; Arkosy, P.; et al. Indolepropionic Acid, a
Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing
Oxidative Stress. Cancers 2020, 12, 2411. [CrossRef]
Ly, M.; Rentas, S.; Vujovic, A.; Wong, N.; Moreira, S.; Xu, J.; Holzapfel, N.; Bhatia, S.; Tran, D.; Minden, M.D.; et al. Diminished
AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance. Cancer Res. 2019, 79, 5799–5811. [CrossRef]
[PubMed]
Iu, M.; Zago, M.; Rico de Souza, A.; Bouttier, M.; Pareek, S.; White, J.H.; Hamid, Q.; Eidelman, D.H.; Baglole, C.J. RelB
attenuates cigarette smoke extract-induced apoptosis in association with transcriptional regulation of the aryl hydrocarbon
receptor. Free Radic. Biol. Med. 2017, 108, 19–31. [CrossRef]

Int. J. Mol. Sci. 2021, 22, 6097

12.

13.

14.

15.

16.

17.

18.

19.
20.
21.
22.

23.
24.
25.
26.
27.
28.
29.
30.

31.
32.
33.
34.
35.

36.

21 of 22

Castaneda, A.R.; Pinkerton, K.E.; Bein, K.J.; Magana-Mendez, A.; Yang, H.T.; Ashwood, P.; Vogel, C.F.A. Ambient particulate
matter activates the aryl hydrocarbon receptor in dendritic cells and enhances Th17 polarization. Toxicol. Lett. 2018, 292, 85–96.
[CrossRef]
van den Bogaard, E.H.; Bergboer, J.G.; Vonk-Bergers, M.; van Vlijmen-Willems, I.M.; Hato, S.V.; van der Valk, P.G.; Schroder, J.M.;
Joosten, I.; Zeeuwen, P.L.; Schalkwijk, J. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J. Clin. Investig.
2013, 123, 917–927. [CrossRef] [PubMed]
Takei, K.; Mitoma, C.; Hashimoto-Hachiya, A.; Takahara, M.; Tsuji, G.; Nakahara, T.; Furue, M. Galactomyces fermentation filtrate
prevents T helper 2-mediated reduction of filaggrin in an aryl hydrocarbon receptor-dependent manner. Clin. Exp. Dermatol.
2015, 40, 786–793. [CrossRef]
Smith, S.H.; Jayawickreme, C.; Rickard, D.J.; Nicodeme, E.; Bui, T.; Simmons, C.; Coquery, C.M.; Neil, J.; Pryor, W.M.;
Mayhew, D.; et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J. Investig. Dermatol.
2017, 137, 2110–2119. [CrossRef]
Jia, Y.; Tao, Y.; Lv, C.; Xia, Y.; Wei, Z.; Dai, Y. Tetrandrine enhances the ubiquitination and degradation of Syk through an AhR-csrc-c-Cbl pathway and consequently inhibits osteoclastogenesis and bone destruction in arthritis. Cell Death Dis. 2019, 10, 38.
[CrossRef] [PubMed]
Giovannoni, F.; Bosch, I.; Polonio, C.M.; Torti, M.F.; Wheeler, M.A.; Li, Z.; Romorini, L.; Rodriguez Varela, M.S.; Rothhammer, V.;
Barroso, A.; et al. AHR is a Zika virus host factor and a candidate target for antiviral therapy. Nat Neurosci. 2020, 23, 939–951.
[CrossRef] [PubMed]
Dou, H.; Duan, Y.; Zhang, X.; Yu, Q.; Di, Q.; Song, Y.; Li, P.; Gong, Y. Aryl hydrocarbon receptor (AhR) regulates adipocyte
differentiation by assembling CRL4B ubiquitin ligase to target PPARgamma for proteasomal degradation. J. Biol. Chem.
2019, 294, 18504–18515. [CrossRef]
Anderson, G.; Carbone, A.; Mazzoccoli, G. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory
Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. Int. J. Mol. Sci. 2021, 22, 1597. [CrossRef]
Roberts, B.J.; Whitelaw, M.L. Degradation of the basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the
ubiquitin/proteasome pathway. J. Biol. Chem. 1999, 274, 36351–36356. [CrossRef] [PubMed]
Davarinos, N.A.; Pollenz, R.S. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded
via the cytosplasmic proteasome following nuclear export. J. Biol. Chem. 1999, 274, 28708–28715. [CrossRef]
Ma, Q.; Baldwin, K.T. 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the
ubiquitin-proteasome pathway. Role of the transcription activaton and DNA binding of AhR. J. Biol. Chem. 2000, 275, 8432–8438.
[CrossRef]
Yang, Y.; Chan, W.K. Selective Autophagy Maintains the Aryl Hydrocarbon Receptor Levels in HeLa Cells: A Mechanism That Is
Dependent on the p23 Co-Chaperone. Int. J. Mol. Sci. 2020, 21, 3449. [CrossRef]
Chen, J.; Yang, Y.; Russu, W.A.; Chan, W.K. The Aryl Hydrocarbon Receptor Undergoes Chaperone-Mediated Autophagy in
Triple-Negative Breast Cancer Cells. Int. J. Mol. Sci. 2021, 22, 1654. [CrossRef]
Embi, N.; Rylatt, D.B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent
protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107, 519–527. [CrossRef] [PubMed]
Linding, R.; Jensen, L.J.; Ostheimer, G.J.; van Vugt, M.A.; Jorgensen, C.; Miron, I.M.; Diella, F.; Colwill, K.; Taylor, L.; Elder, K.;
et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007, 129, 1415–1426. [CrossRef] [PubMed]
Takahashi-Yanaga, F. Activator or inhibitor? GSK-3 as a new drug target. Biochem. Pharmacol. 2013, 86, 191–199. [CrossRef]
Beurel, E.; Grieco, S.F.; Jope, R.S. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacol. Ther.
2015, 148, 114–131. [CrossRef] [PubMed]
Dominguez, J.M.; Fuertes, A.; Orozco, L.; del Monte-Millan, M.; Delgado, E.; Medina, M. Evidence for irreversible inhibition of
glycogen synthase kinase-3beta by tideglusib. J. Biol. Chem. 2012, 287, 893–904. [CrossRef] [PubMed]
Jinwal, U.K.; Trotter, J.H.; Abisambra, J.F.; Koren, J., 3rd; Lawson, L.Y.; Vestal, G.D.; O’Leary, J.C., 3rd; Johnson, A.G.; Jin, Y.;
Jones, J.R.; et al. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J. Biol. Chem.
2011, 286, 16976–16983. [CrossRef]
Li, C.W.; Lim, S.O.; Xia, W.; Lee, H.H.; Chan, L.C.; Kuo, C.W.; Khoo, K.H.; Chang, S.S.; Cha, J.H.; Kim, T.; et al. Glycosylation and
stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 2016, 7, 12632. [CrossRef]
Iitaka, C.; Miyazaki, K.; Akaike, T.; Ishida, N. A role for glycogen synthase kinase-3beta in the mammalian circadian clock.
J. Biol. Chem. 2005, 280, 29397–29402. [CrossRef]
Spengler, M.L.; Kuropatwinski, K.K.; Schumer, M.; Antoch, M.P. A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation. Cell Cycle 2009, 8, 4138–4146. [CrossRef] [PubMed]
Chesire, D.R.; Dunn, T.A.; Ewing, C.M.; Luo, J.; Isaacs, W.B. Identification of aryl hydrocarbon receptor as a putative Wnt/betacatenin pathway target gene in prostate cancer cells. Cancer Res. 2004, 64, 2523–2533. [CrossRef] [PubMed]
Kawajiri, K.; Kobayashi, Y.; Ohtake, F.; Ikuta, T.; Matsushima, Y.; Mimura, J.; Pettersson, S.; Pollenz, R.S.; Sakaki, T.;
Hirokawa, T.; et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.
Proc. Natl. Acad. Sci. USA 2009, 106, 13481–13486. [CrossRef]
Braeuning, A.; Kohle, C.; Buchmann, A.; Schwarz, M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by
the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol. Sci. 2011, 122, 16–25. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2021, 22, 6097

37.

38.
39.
40.
41.
42.
43.
44.
45.

46.

47.

48.

22 of 22

Prochazkova, J.; Kabatkova, M.; Bryja, V.; Umannova, L.; Bernatik, O.; Kozubik, A.; Machala, M.; Vondracek, J. The interplay of
the aryl hydrocarbon receptor and beta-catenin alters both AhR-dependent transcription and Wnt/beta-catenin signaling in liver
progenitors. Toxicol. Sci. 2011, 122, 349–360. [CrossRef]
Bao, W.; Gu, Y.; Ta, L.; Wang, K.; Xu, Z. Induction of autophagy by the MG132 proteasome inhibitor is associated with endoplasmic
reticulum stress in MCF7 cells. Mol. Med. Rep. 2016, 13, 796–804. [CrossRef] [PubMed]
Korolchuk, V.I.; Mansilla, A.; Menzies, F.M.; Rubinsztein, D.C. Autophagy inhibition compromises degradation of ubiquitinproteasome pathway substrates. Mol. Cell 2009, 33, 517–527. [CrossRef] [PubMed]
Lin, S.Y.; Li, T.Y.; Liu, Q.; Zhang, C.; Li, X.; Chen, Y.; Zhang, S.M.; Lian, G.; Liu, Q.; Ruan, K.; et al. GSK3-TIP60-ULK1 signaling
pathway links growth factor deprivation to autophagy. Science 2012, 336, 477–481. [CrossRef] [PubMed]
Nie, T.; Yang, S.; Ma, H.; Zhang, L.; Lu, F.; Tao, K.; Wang, R.; Yang, R.; Huang, L.; Mao, Z.; et al. Regulation of ER stress-induced
autophagy by GSK3beta-TIP60-ULK1 pathway. Cell Death Dis. 2016, 7, e2563. [CrossRef] [PubMed]
Kim, S.; Jho, E.H. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination
regulatory factor 2 (Smurf2). J. Biol. Chem. 2010, 285, 36420–36426. [CrossRef] [PubMed]
Jia, J.; Amanai, K.; Wang, G.; Tang, J.; Wang, B.; Jiang, J. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus
interruptus. Nature 2002, 416, 548–552. [CrossRef]
Chen, S.; Operana, T.; Bonzo, J.; Nguyen, N.; Tukey, R.H. ERK kinase inhibition stabilizes the aryl hydrocarbon receptor:
Implications for transcriptional activation and protein degradation. J. Biol. Chem. 2005, 280, 4350–4359. [CrossRef] [PubMed]
Evans, B.R.; Karchner, S.I.; Allan, L.L.; Pollenz, R.S.; Tanguay, R.L.; Jenny, M.J.; Sherr, D.H.; Hahn, M.E. Repression of aryl
hydrocarbon receptor (AHR) signaling by AHR repressor: Role of DNA binding and competition for AHR nuclear translocator.
Mol. Pharmacol. 2008, 73, 387–398. [CrossRef] [PubMed]
Lang, U.E.; Kocabayoglu, P.; Cheng, G.Z.; Ghiassi-Nejad, Z.; Munoz, U.; Vetter, D.; Eckstein, D.A.; Hannivoort, R.A.; Walsh,
M.J.; Friedman, S.L. GSK3beta phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene
2013, 32, 4557–4564. [CrossRef] [PubMed]
Pappas, B.; Yang, Y.; Wang, Y.; Kim, K.; Chung, H.J.; Cheung, M.; Ngo, K.; Shinn, A.; Chan, W.K. p23 protects the human aryl
hydrocarbon receptor from degradation via a heat shock protein 90-independent mechanism. Biochem. Pharmacol. 2018, 152, 34–44.
[CrossRef]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method. Methods 2001, 25, 402–408. [CrossRef]

